AbbVie Company Profile (NYSE:ABBV)

About AbbVie (NYSE:ABBV)

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry, Sector and Symbol:

Sector: Medical
Industry: Specialty & Advanced Pharmaceuticals
Sub-Industry: Pharmaceuticals
Symbol: NYSE:ABBV
CUSIP: 00287Y10
Web: www.abbvie.com

Capitalization:

Market Cap: $145.12641 billion
Outstanding Shares: 1,594,094,000

Average Prices:

50 Day Moving Avg: $85.49
200 Day Moving Avg: $72.96
52 Week Range: $55.06 - $92.78

P/E:

Trailing P/E Ratio: 22.67
Foreward P/E Ratio: 13.92
P/E Growth: 1.16

Sales & Book Value:

Annual Revenue: $26.71 billion
Price / Sales: 5.50
Book Value: $3.77 per share
Price / Book: 24.45

Dividend:

Annual Dividend: $2.56
Dividend Yield: 2.8%

Profitability:

EBITDA: $11.57 billion
Net Margins: 24.77%
Return on Equity: 150.27%
Return on Assets: 12.52%

Debt:

Debt-to-Equity Ratio: 5.63%
Current Ratio: 1.38%
Quick Ratio: 1.25%

Misc:

Average Volume: 6.28 million shs.
Beta: 1.51
Short Ratio: 5.37

Frequently Asked Questions for AbbVie (NYSE:ABBV)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Friday, September 8th. Stockholders of record on Friday, October 13th will be paid a dividend of $0.64 per share on Wednesday, November 15th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 2.78%. The ex-dividend date of this dividend is Thursday, October 12th. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has approved a stock repurchase plan on Sunday, April 9th 2017, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 5% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board of directors believes its stock is undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings data on Friday, July, 28th. The company reported $1.42 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.40 by $0.02. The firm had revenue of $6.94 billion for the quarter, compared to analyst estimates of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The company's revenue for the quarter was up 7.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.26 earnings per share. View AbbVie's Earnings History.

When will AbbVie make its next earnings announcement?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY17 earnings guidance on Friday, July, 28th. The company provided earnings per share guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.53.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?

16 brokerages have issued 12 month price targets for AbbVie's stock. Their predictions range from $60.00 to $115.00. On average, they expect AbbVie's share price to reach $93.33 in the next twelve months. View Analyst Ratings for AbbVie.

What are analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

1. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well and should continue to do well. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Meanwhile, AbbVie has promising pipeline with several pivotal data readouts and regulatory milestones due in the second half. Maviret, approved recently, has the potential to rejuvenate AbbVie’s struggling HCV franchise. AbbVie’s shares have outperformed the industry this year so far. However, though Humira is doing well, the company is concerned about the product’s long-term growth prospects, given the potential biosimilar competition. Viekira also faces intense pricing and competitive pressure in the HCV market. Estimates have gone up slightly ahead of the company’s Q3 earnings release. AbbVie has had a mixed record of earnings surprises in the recent quarters." (10/17/2017)
2. UBS AG analysts commented, "For other pipeline products, we already included appropriate risk-adj estimates and in some cases significant risk adj sales (Rova-T)," (9/25/2017)
3. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)

Who are some of AbbVie's key competitors?

Some companies that are related to AbbVie include ConvaTec Group PLC (CTEC), Mallinckrodt PLC (MNK), Advanced Accelerator Applications S.A. (AAAP), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Aimmune Therapeutics (AIMT), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), Novan (NOVN), CorMedix (CRMD), Check-Cap (CHEK), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:

Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
William J. Chase, Executive Vice President, Chief Financial Officer
Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
Carlos Alban, Executive Vice President - Commercial Operations
Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
Timothy J. Richmond, Senior Vice President - Human Resources
Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
Robert A. Michael, Vice President, Controller
Robert J. Alpern M.D., Independent Director

Who owns AbbVie stock?

AbbVie's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Park National Corp OH (0.02%), Tandem Investment Advisors Inc. (0.01%), Osborn Williams & Donohoe LLC (0.01%), Neville Rodie & Shaw Inc. (0.01%), Fulton Bank N.A. (0.00%) and Bridges Investment Management Inc. (0.00%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including Bridges Investment Counsel Inc., Private Asset Management Inc., Fulton Bank N.A., Osborn Williams & Donohoe LLC, Neville Rodie & Shaw Inc., Park National Corp OH, Bridges Investment Management Inc. and Tandem Investment Advisors Inc.. Company insiders that have sold AbbVie stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was acquired by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp, Eqis Capital Management Inc. and Amarillo National Bank. View Insider Buying and Selling for AbbVie.

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of AbbVie stock can currently be purchased for approximately $92.17.

MarketBeat Community Rating for AbbVie (NYSE ABBV)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		606 (Vote Outperform)
Underperform Votes:		349 (Vote Underperform)
Total Votes:		955

MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for AbbVie (NYSE:ABBV) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	6 Hold Ratings, 10 Buy Ratings
Consensus Rating:	Buy (Score: 2.63)
Consensus Price Target:	$93.33 (1.26% upside)

Consensus Price Target History for AbbVie (NYSE:ABBV)

Analysts' Ratings History for AbbVie (NYSE:ABBV)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
10/16/2017	Jefferies Group LLC	Boost Price Target	Buy	$107.00 -> $115.00	N/A
10/13/2017	Barclays PLC	Boost Price Target	Equal Weight	$90.00	N/A
10/11/2017	Cowen and Company	Upgrade	Market Perform -> Outperform	$91.17 -> $105.00	N/A
10/2/2017	Leerink Swann	Upgrade	Market Perform -> Outperform	$89.00 -> $106.00	Medium
10/1/2017	Credit Suisse Group	Reiterated Rating	Neutral	$74.00 -> $94.00	Medium
9/30/2017	Evercore ISI	Reiterated Rating	Outperform	$95.00 -> $100.00	Medium
9/28/2017	BMO Capital Markets	Reiterated Rating	Hold	$66.00	Low
9/29/2017	Argus	Boost Price Target	Buy	$90.00 -> $110.00	Low
9/29/2017	Morgan Stanley	Boost Price Target	Equal Weight	$70.00 -> $95.00	Low
9/28/2017	Deutsche Bank AG	Boost Price Target	Hold	$88.00	Low
9/15/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$100.00	High
9/13/2017	SunTrust Banks, Inc.	Reiterated Rating	Buy	$95.00	Low
9/8/2017	Goldman Sachs Group, Inc. (The)	Reiterated Rating	Buy	$85.00 -> $100.00	Low
6/22/2017	Societe Generale	Upgrade	Hold -> Buy		Low
12/8/2016	William Blair	Reiterated Rating	Outperform	$76.00	N/A
11/28/2016	Citigroup Inc.	Downgrade	Buy -> Neutral	$60.00	N/A
9/8/2016	J P Morgan Chase & Co	Downgrade	Overweight -> Neutral	$75.00 -> $73.00	N/A
9/1/2016	Raymond James Financial, Inc.	Initiated Coverage	Outperform	$82.00	N/A
12/18/2015	Atlantic Securities	Initiated Coverage	Neutral	$59.00	N/A

(Data available from 10/18/2015 forward)

Earnings History for AbbVie (NYSE:ABBV)

Earnings by Quarter for AbbVie (NYSE:ABBV)

Earnings History by Quarter for AbbVie (NYSE ABBV)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/27/2017		$1.38					N/A
7/28/2017	Q2 2017	$1.40	$1.42	$6.93 billion	$6.94 billion	View	N/A
4/27/2017	Q1 2017	$1.26	$1.28	$6.49 billion	$6.54 billion	View	N/A
1/27/2017	Q416	$1.20	$1.20	$6.92 billion	$6.78 billion	View	Listen
10/28/2016	Q316	$1.21	$1.21	$6.55 billion	$6.43 billion	View	Listen
7/29/2016	Q216	$1.20	$1.26	$6.20 billion	$6.43 billion	View	Listen
4/28/2016	Q116	$1.14	$1.15	$6.03 billion	$5.96 billion	View	Listen
1/29/2016	Q415	$1.12	$1.13	$6.41 billion	$6.36 billion	View	Listen
10/30/2015	Q315	$1.08	$1.13	$5.90 billion	$4.94 billion	View	Listen
7/24/2015	Q215	$1.06	$1.08	$5.60 billion	$5.48 billion	View	Listen
4/23/2015	Q115	$0.85	$0.94	$718.50 million	$5.04 billion	View	Listen
1/30/2015	Q414	$0.86	$0.89	$5.34 billion	$5.45 billion	View	Listen
10/31/2014	Q3	$0.77	$0.89	$4.82 million	$5.02 million	View	Listen
7/25/2014	Q214	$0.76	$0.82	$4.70 billion	$4.93 billion	View	Listen
4/25/2014	Q114	$0.68	$0.71	$4.33 billion	$4.56 billion	View	Listen
1/31/2014	Q413	$0.82	$0.82	$5.10 billion	$5.11 billion	View	Listen
10/25/2013	Q313	$0.78	$0.82	$4.52 billion	$4.66 billion	View	Listen
7/26/2013	Q2 2013	$0.79	$0.92	$4.54 billion	$4.69 billion	View	Listen
4/26/2013	Q1 2013	$0.67	$0.68	$4.17 billion	$4.33 billion	View	Listen

(Data available from 1/1/2011 forward)

Earnings Estimates for AbbVie (NYSE:ABBV)

Current Year EPS Consensus Estimate: $5.54 EPS
Next Year EPS Consensus Estimate: $6.62 EPS

Current Dividend Information for AbbVie (NYSE:ABBV)

Next Dividend:	11/15/2017
Annual Dividend:	$2.56
Dividend Yield:	2.78%
Dividend Growth:	12.50% (3 Year Average)
Payout Ratio:	62.90% (Trailing 12 Months of Earnings) 46.21% (Based on This Year's Estimates) 38.67% (Based on Next Year's Estimates)
Track Record:	44 Years of Consecutive Dividend Growth

Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

Dividend History by Quarter for AbbVie (NYSE ABBV)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/8/2017	Quarterly	$0.64	2.94%	10/12/2017	10/13/2017	11/15/2017
6/23/2017	quarterly	$0.64	3.52%	7/12/2017	7/14/2017	8/15/2017
2/17/2017	quarterly	$0.64	4.14%	4/11/2017	4/13/2017	5/15/2017
10/28/2016	quarterly	$0.64	4.44%	1/11/2017	1/13/2017	2/15/2017
9/12/2016	quarterly	$0.57	3.56%	10/12/2016	10/14/2016	11/15/2016
6/17/2016	quarterly	$0.57	3.8%	7/13/2016	7/15/2016	8/15/2016
2/19/2016	quarterly	$0.57	4.2%	4/13/2016	4/15/2016	5/16/2016
11/2/2015	quarterly	$0.57	3.6%	1/13/2016	1/15/2016	2/16/2016
9/14/2015	quarterly	$0.51	3.46%	10/13/2015	10/15/2015	11/14/2015
6/19/2015	quarterly	$0.51	2.94%	7/13/2015	7/15/2015	8/14/2015
2/20/2015	quarterly	$0.51	3.33%	4/13/2015	4/15/2015	5/15/2015
10/20/2014	quarterly	$0.49	3.48%	1/13/2015	1/15/2015	2/13/2015
9/19/2014	quarterly	$0.42	2.86%	10/10/2014	10/15/2014	11/17/2014
6/19/2014	quarterly	$0.42	3.15%	7/11/2014	7/15/2014	8/15/2014
2/20/2014	quarterly	$0.42	3.29%	4/11/2014	4/15/2014	5/15/2014
12/12/2013	quarterly	$0.40	3.06%	1/13/2014	1/15/2014	2/14/2014
9/19/2013	quarterly	$0.40	3.34%	10/10/2013	10/15/2013	11/15/2013
6/20/2013	quarterly	$0.40	3.75%	7/11/2013	7/15/2013	8/15/2013
2/15/2013	quarterly	$0.40	4.19%	4/11/2013	4/15/2013	5/15/2013
1/7/2013	special	$0.40		1/11/2013	1/15/2013	2/15/2013
1/4/2013	quarterly	$0.40			1/15/2013	2/15/2013

(Data available from 1/1/2013 forward)

Insider Trading and Institutional Ownership History for AbbVie (NYSE:ABBV)

Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 68.25%

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Insider Trades by Quarter for AbbVie (NYSE:ABBV)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/28/2017	Robert A Michael	VP	Sell	6,699	$88.00	$589,512.00
9/11/2017	Azita Saleki-Gerhardt	SVP	Sell	8,300	$85.02	$705,666.00
8/7/2017	Richard A Gonzalez	Chairman	Sell	193,131	$71.00	$13,712,301.00
8/4/2017	Richard A Gonzalez	Chairman	Sell	87,899	$71.02	$6,242,586.98
8/3/2017	Richard A Gonzalez	CEO	Sell	65,861	$71.00	$4,676,131.00
7/31/2017	Edward J Rapp	Director	Buy	4,000	$70.45	$281,800.00
7/31/2017	Henry O Gosebruch	Insider	Sell	18,000	$70.09	$1,261,620.00
6/14/2017	Carlos Alban	EVP	Sell	45,800	$70.00	$3,206,000.00
6/14/2017	Laura J Schumacher	Insider	Sell	79,800	$70.00	$5,586,000.00
5/19/2017	Richard A Gonzalez	Chairman	Sell	71,235	$65.49	$4,665,180.15
5/18/2017	William J Chase	CFO	Sell	38,300	$65.35	$2,502,905.00
5/4/2017	Carlos Alban	EVP	Sell	43,000	$67.00	$2,881,000.00
3/10/2017	Laura J Schumacher	Insider	Sell	40,000	$65.26	$2,610,400.00
3/10/2017	Robert A Michael	VP	Sell	5,132	$65.29	$335,068.28
3/10/2017	Timothy J Richmond	SVP	Sell	22,451	$65.29	$1,465,825.79
3/8/2017	Richard A Gonzalez	Chairman	Sell	72,016	$64.25	$4,627,028.00
12/2/2016	William J Chase	CFO	Sell	6,600	$59.19	$390,654.00
9/7/2016	Laura J Schumacher	Insider	Sell	50,000	$65.00	$3,250,000.00
6/24/2016	Laura J Schumacher	EVP	Sell	186,106	$60.03	$11,171,943.18
6/2/2016	Richard A Gonzalez	CEO	Sell	285,953	$63.82	$18,249,520.46
5/11/2016	Richard A Gonzalez	CEO	Sell	39,000	$63.80	$2,488,200.00
5/10/2016	Carlos Alban	EVP	Sell	47,438	$63.52	$3,013,261.76
5/10/2016	Thomas A Hurwich	VP	Sell	6,000	$63.59	$381,540.00
5/10/2016	Timothy J Richmond	SVP	Sell	21,583	$63.52	$1,370,952.16
3/8/2016	Laura J Schumacher	EVP	Sell	25,000	$56.09	$1,402,250.00
3/1/2016	Timothy J Richmond	SVP	Sell	12,866	$55.05	$708,273.30
4/28/2015	Richard A Gonzalez	CEO	Sell	102,964	$64.67	$6,658,681.88
3/2/2015	Laura J Schumacher	EVP	Sell	25,000	$60.30	$1,507,500.00
3/2/2015	Timothy J Richmond	SVP	Sell	14,388	$60.33	$868,028.04
12/22/2014	William J Chase	CFO	Sell	8,495	$68.00	$577,660.00
3/4/2014	Richard Gonzalez	CEO	Sell	4,799	$51.20	$245,708.80
3/3/2014	Azita Saleki-Gerhardt	SVP	Sell	2,443	$50.25	$122,760.75
3/3/2014	Carlos Alban	EVP	Sell	2,882	$50.09	$144,359.38
3/3/2014	William Chase	CFO	Sell	3,948	$50.22	$198,268.56
9/17/2013	Azita Saleki-Gerhardt	SVP	Sell	10,473	$45.84	$480,082.32
8/19/2013	Azita Saleki-Gerhardt	SVP	Sell	1,270	$43.01	$54,622.70
8/12/2013	Azita Saleki-Gerhardt	SVP	Sell	8,851	$44.91	$397,498.41
3/11/2013	Edward J Rapp	Director	Buy	2,500	$37.67	$94,175.00
2/4/2013	Frederick H Waddell	Director	Buy	2,000	$37.05	$74,100.00

(Data available from 1/1/2013 forward)

Headline Trends for AbbVie (NYSE:ABBV) Latest Headlines for AbbVie (NYSE:ABBV)

Source:

Date	Headline
	Where to Find Value in Healthcare Stocks finance.yahoo.com - October 17 at 8:19 PM
	Kessler Investment Group, LLC Buys Apple Inc, The Home Depot Inc, Amazon. ... www.nasdaq.com - October 17 at 3:17 PM
	J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales finance.yahoo.com - October 17 at 3:17 PM
	Sanofi/Regeneron's Dupixent Succeeds in Phase II Study finance.yahoo.com - October 17 at 3:17 PM
	Analysts Anticipate AbbVie Inc. (ABBV) Will Post Earnings of $1.38 Per Share www.americanbankingnews.com - October 17 at 6:28 AM
	AbbVie (ABBV) a Buy on Healthy Earnings Momentum investorplace.com - October 16 at 1:22 PM
	AbbVie Inc. (ABBV) Rating Increased to Outperform at Cowen and Company www.americanbankingnews.com - October 16 at 12:50 AM
	Better Buy: AbbVie Inc. vs. Merck -- The Motley Fool - Motley Fool www.fool.com - October 15 at 1:22 AM
	Better Buy: AbbVie Inc. vs. Merck finance.yahoo.com - October 14 at 8:19 PM
	AbbVie Inc. (ABBV) Receives "Neutral" Rating from UBS AG www.americanbankingnews.com - October 13 at 10:44 PM
	Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock? finance.yahoo.com - October 13 at 8:23 PM
	New Law May Pressure Drug Prices finance.yahoo.com - October 13 at 8:23 PM
	Why 2017 Could Be This Stock's Best Year Yet finance.yahoo.com - October 13 at 8:23 PM
	AbbVie Inc. (ABBV) PT Raised to $90.00 at Barclays PLC www.americanbankingnews.com - October 13 at 7:34 PM
	Fundamental Equity Analysis – Consolidated Research on Johnson & Johnson, Home Depot, Adobe, Disney, AbbVie, and eBay – Developing Opportunities, Future Expectations, and Projections finance.yahoo.com - October 13 at 3:18 PM
	Cancer Space Update: Lung & Breast Cancer Studies in Focus finance.yahoo.com - October 13 at 3:18 PM
	4 things that might surprise investors this earnings season finance.yahoo.com - October 13 at 3:18 PM
	AbbVie, Abbott duck Depakote off-label marketing case on appeal - Reuters www.reuters.com - October 12 at 8:21 PM
	Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock? - Nasdaq www.nasdaq.com - October 12 at 3:18 PM
	AbbVie Reaches Analyst Target Price - Nasdaq www.nasdaq.com - October 12 at 3:18 PM
	Top 5 Biotech Stocks for 2017 finance.yahoo.com - October 12 at 3:18 PM
	AbbVie: You're Upgrading It…Now? finance.yahoo.com - October 11 at 8:29 PM
	Is AbbVie the Best Dividend Stock in Healthcare? finance.yahoo.com - October 11 at 8:29 PM
	How Safe Is AbbVie's Dividend? finance.yahoo.com - October 11 at 8:29 PM
	How Safe Is AbbVie's Dividend? www.fool.com - October 11 at 7:40 PM
	Hurricane-related damage could cause shortages of 40 drugs - FDA - Seeking Alpha seekingalpha.com - October 11 at 3:27 PM
	AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for October 12, 2017 - Nasdaq www.nasdaq.com - October 11 at 3:26 PM
	BRIEF-AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology www.reuters.com - October 10 at 8:19 PM
	3 Healthcare Dividend Stocks Ideal for Retirees finance.yahoo.com - October 10 at 8:19 PM
	AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology finance.yahoo.com - October 10 at 8:19 PM
	Hold Recommendation for AbbVie (ABBV) Stock Kept - Investorplace.com investorplace.com - October 10 at 3:19 PM
	California enacts law aimed at corralling high drug prices - Seeking Alpha seekingalpha.com - October 10 at 3:19 PM
	Ex-Dividend Reminder: Foot Locker, Patterson Companies and AbbVie - Nasdaq www.nasdaq.com - October 10 at 3:19 PM
	AbbVie (ABBV) and Its Competitors Head to Head Comparison www.americanbankingnews.com - October 9 at 6:28 PM
	AbbVie to Host Third-Quarter 2017 Earnings Conference Call finance.yahoo.com - October 9 at 3:29 PM
	Hold Recommendation for AbbVie (ABBV) Stock Kept investorplace.com - October 9 at 11:37 AM
	AbbVie's Fast Becoming a Top Stock to Buy Now - Motley Fool www.fool.com - October 8 at 3:15 PM
	AbbVie's Fast Becoming a Top Stock to Buy Now finance.yahoo.com - October 8 at 3:15 PM
	3 Best Healthcare Dividend Aristocrat Stocks You Can Buy Right Now finance.yahoo.com - October 8 at 3:15 PM
	Contrasting AbbVie (ABBV) & Its Rivals www.americanbankingnews.com - October 7 at 6:28 PM
	AbbVie Inc. (ABBV) Declares $0.64 Quarterly Dividend www.americanbankingnews.com - October 7 at 10:50 AM
	Seeger Weiss LLP Reports: Jury Awards over $140 Million in Compensatory and Punitive Damages to Man Injured by AbbVie Drug AndroGel www.bizjournals.com - October 6 at 8:44 PM
	AbbVie hit with $140 mln verdict in AndroGel trial -lawyer - Reuters www.reuters.com - October 6 at 3:42 PM
	Second US jury finds AbbVie misrepresented risks of AndroGel - Reuters www.reuters.com - October 6 at 3:42 PM
	Best Healthcare Stocks: AbbVie - Seeking Alpha seekingalpha.com - October 6 at 3:42 PM
	Gilead Sciences & AbbVie: Mother Always Told Me to Share finance.yahoo.com - October 6 at 3:42 PM
	Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now? www.fool.com - October 6 at 7:43 AM
	AbbVie hit with $140 mln verdict in AndroGel trial www.nasdaq.com - October 5 at 8:09 PM
	AbbVie hit with $140 mln verdict in AndroGel trial -lawyer finance.yahoo.com - October 5 at 8:09 PM
	AbbVie suffers second trial loss over testosterone drug risk seekingalpha.com - October 5 at 7:19 PM